Pharmacy

The FINANCIAL -- On April 29 Biogen and AbbVie announced that the U.S. Food and Drug Administration (FDA) has accepted for review the companies’ Biologics License Application (BLA) requesting marketing approval of ZINBRYTA (daclizumab high-yield process) for relapsing forms of multiple sclerosis ...

More Articles ...

More Articles ...

The FINANCIAL -- Drug maker Novo Nordisk A/S on April 30 raised its financial guidance for 2015 as it reported a strong rise in profit and announced that Chief Executive Lars Rebien Sorensen will ...

Videos

Watch the video